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http://www.biomedcentral.com/1471-2407/12/267RESEARCH ARTICLE Open AccessTumor suppressor BLU inhibits proliferation of
nasopharyngeal carcinoma cells by regulation of
cell cycle, c-Jun N-terminal kinase and the cyclin
D1 promoter
Xiangning Zhang1,2*, Hui Liu1,2, Binbin Li1,2, Peichun Huang1,2, Jianyong Shao3 and Zhiwei He1,2*Abstract
Background: Tumor suppressor genes function to regulate and block tumor cell proliferation. To explore the
mechanisms underlying the tumor suppression of BLU/ZMYND10 gene on a frequently lost human chromosomal
region, an adenoviral vector with BLU cDNA insert was constructed.
Methods: BLU was re-expressed in nasopharyngeal carcinoma cells by transfection or viral infection. Clonogenic
growth was assayed; cell cycle was analyzed by flow cytometry-based DNA content detection; c-Jun N-terminal
kinase (JNK) and cyclin D1 promoter activities were measured by reporter gene assay, and phosphorylation was
measured by immunoblotting. The data for each pair of groups were compared with Student t tests.
Results: BLU inhibits clonogenic growth of nasopharyngeal carcinoma cells, arrests cell cycle at G1 phase,
downregulates JNK and cyclin D1 promoter activities, and inhibits phosphorylation of c-Jun.
Conclusions: BLU inhibits growth of nasopharyngeal carcinoma cells by regulation of the JNK-cyclin D1 axis to
exert tumor suppression.
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Tumor suppressor genes (TSGs) are implicated in the
genesis of cancer following loss of function, and such
losses normally contribute to deficiencies in cell cycle
modulation and apoptosis induction. These losses of cell
function are usually either due to homozygous deletion
or hypermethylation on promoter regions [1], which
would normally function to inhibit cell proliferation and
thereby suppress tumor growth. The short arm of
human chromosome 3 (3p) harbors a 670 kb region,* Correspondence: Zhangxn_2006@126.com; Zhiweihe688@yahoo.com
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reproduction in any medium, provided the orwhich is frequently deleted in various cancers. A min-
imal candidate region of 120 kb has been identified, and
the affected genes include Ras-associated factor 1
(RASSF1), and β-catenin in lung cancer (BLU) [2,3].
Nasopharyngeal carcinoma (NPC) is a cancer of head
and neck squamous cells, and is endemic in southern
China and certain regions of Southeast Asia. Its occur-
rence involves the interaction of host genetic materials
with environmental factors, notably infection by Epstein-
Barr virus (EBV). EBV plays a crucial role in the clonal
expansion of pre-malignant cells [4], and regionally
prevalent viral strains may be responsible for carcino-
genesis [5]. Genetic or epigenetic changes of BLU are
frequent in NPC [6-8].
RASSF1 isoform A (RASSF1A), located on the 3p21
region, is one of the TSGs clustered on the 120 kb frag-
ment affected during the genesis of human tumors, as
described above. It codes for a zinc finger protein and
transcriptionally regulates a panel of genes to modulateLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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RASSF1A inhibits cyclin D1 and arrests the cell cycle in
the G1 phase [10]. C-Jun N terminal kinase (JNK) is a
member of the mitogen activated kinase (MAPK) family.
It is activated by extracellular stress and other stimuli,
and in turn triggers a kinase cascade and contributes
to the formation of dimeric transcription factor AP1
on phosphorylating c-Jun. In line with the expression
of cyclin D1 induced by c-Jun [11], the downregula-
tion of cyclin D1 is attributed to JNK inhibition by
RASSF1A [12].
Studies have shown that BLU is lost in various human
tumors. When transfected into HONE-1 cells derived
from NPC, BLU inhibits the tumorigenesis of nude mice
xenografts [13]. This result suggests that expression of
BLU downregulates cell proliferation either through
apoptosis or by cell cycle regulation. The candidate
TSGs from the 3p region were transferred to lung can-
cer lines to evaluate their tumor suppression. Some of
these genes have the potential to induce apoptosis upon
expression. Apoptosis, however, was not observed in
BLU-expressing cells [14]. BLU encodes a protein of 440
amino acid residues, which has a zinc finger MYND
(myeloid Nervy deformed epidermal auto-regulatory
factor-1 (DEAF-1)) domain, ZMYND [3]. ZMYND
domain-containing proteins define a protein family
whose members associate with molecules such as co-
repressors to regulate transcription and may modulate
the process of malignant transformation. BLU is alterna-
tively termed ZMYND10, and is structurally similar to
ZMYND2 [2,3]. ZYMND2 forms a fusion protein with
acute myeloid leukemia-1 (AML-1) due to a t(8;21)
chromosomal translocation, which is the most frequent
chromosomal aberration seen in acute myeloid leukemia.
AML-1-dependent transactivation is inhibited by fusion
with ZMYND2 (also known as ETO) [15].
The ZMYND is the only functional domain present
within the BLU protein molecule, and it is a potential
binding site for co-repressors of transcription, such as
nuclear co-repressor (NcoR), mSin 3A, and the histone
deacetylases [16]. The ability of BLU to regulate tran-
scription is speculated to influence the level of prolifera-
tion regulators, and engagement of signaling pathways
involving JNK and cyclin D1 may mechanistically eluci-
date the tumor suppressive role played by BLU.
Methods
Cells and plasmids
CNE-1 and CNE-2 lines derived from well differentiated
and undifferentiated NPCs from Chinese patients, re-
spectively, were either obtained from the nitrogen stock
in our department or purchased from the Cell Bank,
Institute of Life Science, Chinese Academy of Science,
Shanghai, China. The esophageal cancer line EC109 wasobtained from the laboratory of Professor Qian Tao,
Chinese University of Hong Kong. The full-length
cDNA of BLU/ZMYND10 (GenBank accession no.
NM_015896) (Additional file 1)was chemically synthe-
sized and inserted into the SalI-SacI sites of the
pCD316-EGFP plasmid (Viral Gene Transfer Company,
Beijing, China), and the inserted fragment was con-
firmed by sequencing. BLU and TP53 inserted in the
pcDNA3.1 vector were provided by Professors Qian
Tao and Bert Vogelstein, Johns Hopkins University,
Baltimore, MD, USA, respectively. The reporter plasmid
pRTU14 with an AP-1 region located upstream of the
coding gene of luciferase was a gift from Dr Arnd
Kieser, Helmholtz Zentrum München, Munich,
Germany [17], and a cyclin D1 promoter reporter
plasmid-1745 CD1 LUC containing the full-length cyc-
lin D1 gene promoter was a kind gift from Dr Richard
Pestell, Thomas Jefferson University, Philadelphia, PA,
USA [11]. The control reporter plasmid, pRL-TK
expressing Renilla luciferase, was purchased from
Promega (Beijing, China).
Antibodies and reagents
Goat anti-human BLU/ZMYND10 protein antibody was
purchased from Abcam (Cambridge, UK). Rabbit anti-
c-Jun and anti-phospho-c-Jun (Ser73) antibodies, and
anti-cyclin D1 antibody were purchased from Cell
Signaling Technology (Danvers, MA, USA). Mouse anti-
human actin monoclonal antibody (mAB) and clone C4
was purchased from Millipore (Beijing, China). Ultra Red
Odyssey-labeled rabbit anti-mouse and rat anti-rabbit
immunoglobulins were purchased from Invitrogen
(Guangzhou, China). Transfection reagent FuGene HD
was purchased from Roche (Shanghai, China). Luciferin
substrate and stop reagent were purchased from Promega
(China).
Production of Ad-BLU-enhanced green fluorescence
protein (EGFP) virions and infection of NPC-derived cells
Ad-BLU-EGFP virions were prepared by transfection of
pCD316-BLU to packaging 293 cells. CNE2 cells were
incubated with different doses of the viral stock, and
grown for 48 h on sterile cover slips placed on the bot-
tom of six-well culture plates.
Confocal microscopy
At the time of harvest, cover slips seeded with transfected
cells were washed with phosphate-buffered saline (PBS),
fixed with 1:1 acetone-methanol, and stained with propi-
dium iodide (PI; Invitrogen), and then mounted on slides
with medium containing an antifade reagent. Images were
captured at × 400 magnification using Laser Sharp Soft-
ware (Macrologic Solutions, Albuquerque, NM).
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CNE-2 cells were seeded in 6- or 12-well culture plates,
and incubated at 37°C with 5% CO2. Cells were then
transfected with 0.5 μg (12-well plates) or 1 μg (six-well
plates) DNA by mixing with FuGene HD, as indicated in
the manual provided by the manufacturer. Cells were
then incubated for 24 h.
Colony formation inhibition assays
Assays were conducted as previously described [18]. A
total of 1 × 105 CNE2 or EC109 cells were seeded in 12-
well plates, and were transfected with pcDNA3.1-BLU,
pcDNA3.1-TP53, empty vector pcDNA3.1 or were left
untransfected. After 48 h, 1 × 104 cells were seeded in
triplicate in 6-well culture plates, and cultured with
complete medium containing 500 μg/ml G418 (Gibco
Biotechnology) for 2 weeks. Cells were then fixed with
ice-cold acetone-methanol (1:1), stained with gentian
violet and washed with sterile PBS. Colonies containing
more than 50 cells were counted, and comparisons were
made between BLU-, TP53- and mock-transfected and
untransfected cells. The experiment was repeated at least
three times, and the data were evaluated statistically.
Luciferase assays
CNE-2 cells were co-transfected with expression vectors
(BLU or empty vector), JNK or cyclin D1 promoter
reporters, and the internal control plasmid TK-RL for
24 h, and then harvested by lysis with 1× Passive Lysis
Buffer (Promega, China). Lysate was added to each well
of a non-transparent 96-well plate and mixed with luci-
ferin. The luciferase activity was measured with a BioTek
ELISA reader, followed by measurement of the firefly
luciferase activity. Luciferase activity was then quenched
with GLO Stop reagent, and new luciferin was added.
The data were analyzed with Gen 5 Wizard software
(BioTek, Beijing, China). The ratios of the two readings
were calculated and interpreted as the calibrated re-
porter activity of the transcription gene. The data were
presented as mean± standard deviation (SD), and were
derived from at least three independent experiments.
Flow cytometry
Monolayers of up to 2 × 105 cells transfected with
pCD316-BLU M PI diluted with staining buffer (100
mMTris, pH7.4, 150 mM NaCl, 1 mMCaC12 or empty
vector were grown on 6-well culture plates for 24 h or
48 h. Following harvest, they were fixed with absolute
ethanol, stained with 3 μ2 M PI diluted with staining
buffer (100 mM Tris, pH7.4, 150 mM NaCl, 1 mM
CaCl2, PI diluted with staining buffer (100 mM Tris,
pH 7.4, 150 mM NaCl, 1 mM CaCl2 , 0.5 mM MgCl2,
0.1% Nonidet P-40) and detected using a FACS Canto
(Becton Dickinson, San Jose, CA, USA). The DNAcontent of the cells was analyzed using Win Cycle32
software (Phoenix Flow Systems Inc., San Diego, CA,
USA).
Western blotting
Transfected cells were pelleted and dissolved in
2× loading buffer (130 mM Tris, pH 6.8, 4% sodium
dodecyl sulfate (SDS), 20% glycerol, 10% mercaptoetha-
nol). Total protein was separated by SDS-PAGE and
electro-blotted to nitrocellulose membranes, then
probed with appropriate primary antibodies diluted in
blocking buffer at 1: 500 (Goat anti-human BLU;
Abcam) or 1: 1,000[Rabbit anti-c-Jun and anti-
phospho-c-Jun (Ser73) antibodies, and anti-cyclin D1
antibody, CST)] with 5% nonfat milk in PBS overnight
at 4°C or 1 h at room temperature. After washing with
0.1% Tween-20 in PBS, membranes were incubated
with secondary antibodies at 1:10,000 dilution. Blots
were developed in an Odyssey Infrared Imager
(LI-COR Bioscience, Lincoln, NE, USA).
Statistical analysis
All quantitative data were obtained from three inde-
pendent tests, and presented as mean± SD. Student t-
tests were used to compare the mean values of each
group, and in all cases, P <0.05 was considered statisti-
cally significant.
Results and discussion
BLU was efficiently transferred by adenoviral vector to
CNE2 cells. To study the tumor suppressive effects of
BLU, cDNA was chemically synthesized and inserted
into pCD316 adenoviral expression vector. After trans-
fection into a packaging cell line 293, a total amount of
1 × 1012 viral particles/ml were obtained. Two NPC
derived lines, CNE-1 and CNE-2 were chosen to study
the effect of ectopic expression of BLU on the growth of
NPC because the BLU expression is lost in these cells
due to the presence of promoter hypermethyaltion [8].
BLU has been shown to be downregulated in other lines,
but those lines still exhibit basal expression, for example,
the EBV positive C666-1 [8]. Supernatant containing vir-
ions, termed Ad BLU, with 10, 50, 100, 200, or 400
plague-forming units (PFU) per cell, as previously
described [19], were co-incubated with CNE-2 cells.
Cells were transfected with EGFP fused with the target
gene, and there was no cytotoxicity at a dose of 100 PFU
per cell. Thus, this dose was considered optimal for BLU
transfer (Figure 1A–F).
In contrast, the results obtained for determination of
the optimal infection dose of Ad BLU in CNE-1 cells dif-
fered: (Additional file 2) these data are to be further con-
firmed using other approaches before in vivo studies are
performed. Counterstaining with PI revealed a mixed
Figure 1 BLU expression in CNE-2 cells following adenovirus-mediated gene transfer. (A–F) CNE 2 cells plated in six-well culture plates
were challenged with 0, 10, 50, 100, 200, or 400 PFU viral particles. (G-I) Cells were grown on cover slips, fixed and viewed with a confocal
microscope at a resolution of × 100. The cells were identically manipulated, stained with 3 M PI, and viewed with confocal microscope at a
resolution of × 400 for EGFP. The overlapping signals were analyzed on merged figures. The arrows indicate cytoplasmic localization of BLU
protein.
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nuclear localization of overexpressed BLU. Our results
were in line with the Gene Ontology data (http://www.
uniprot.org/uniprot/O75800), suggesting predominant
cytoplasm distribution (Figure 1F–I).
Inhibition of clonogenic growth and cell cycle entry by
expression of BLU in CNE-2 cells
Both BLU-expressing plasmid and recombinant BLU
adenovirus Ad BLU were used in the present study. The
potential inhibition of growth by BLU was assayed with
pcDNA3.1 vector, and the effect was compared with that
of the tumor suppressor TP53 expressed from the same
eukaryotic vector. The effect was tested in two malig-
nant lines of epithelial origin. CNE-2 cells are an NPC
line that is negative for BLU expression [8], and EC109
cells were derived from an esophageal cancer patient in
which the expression of yh is absent. Ectopic expression
of BLU significantly suppressed the number of coloniesby more than 50% of the mock transfected cells compar-
able with the extent seen in TP53-transfected cells
(Figure 2A), implying suppression of tumorigenicity by
BLU.
Tetracycline-regulated BLU suppresses tumor forma-
tion, while downregulation of BLU can promote tumor
growth in nude mice with human NPC xenografts [13].
However, forced expression of BLU in lung cancer cells
fails to induce apoptosis [14]. Upon staining with DNA
dye, PI-fragmented nuclei were not visible by confocal
microscopy (Figure 1A–I). The suppression of cell pro-
liferation could be promoted by blocking cell cycle
entry. To identify the nature of the cell cycle arrest,
CNE2 cells were transfected with pCD316-BLU and
empty vector, and examined for DNA content by
FACS. Analysis of PI incorporation shows that in com-
parison to the mock transfected cells, the majority of
CNE-2 cells expressing BLU were in the G1 phase of
the cell cycle (Figure 2D–F).
Figure 2 BLU expression exerts growth inhibitory activity and cell cycle arrest. (A) NPC-derived CNE-2 line and esophageal carcinoma-
derived EC109 line were transfected with empty pcDNA3.1 vector, tumor suppressor TP53 or BLU. Cells were cultured in complete medium
supplemented with 500 μg/ml G418 for up to 2 weeks, harvested and stained with gentian violet. (B) Summary of the results in (A). The colonies
obtained for each experimental condition were counted and the numbers were presented as mean± standard deviation. (C) and (D) CNE-2 cells
were transfected with vector or pCD316-BLU and stained with PI diluted in assay buffer. The DNA contents were measured with FACS and
analyzed with Win Cycle32 software. (E) Results of FACS analysis. The numbers 1, 2, and 3 depict the populations of cells in G1, G2/M and S
phases. BLU expression arrested the cells in G1 phase, as manifested by the increase in this population. The data is presented as mean± SD
derived from at least three independent experiments.
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expression
Cyclin D1 protein is involved in the process of permit-
ting cells to enter S phase. Consistent with its role in
regulating G1/S phase progression, BLU expression dra-
matically reduced cyclin D1 level (Figure 3A). This is in
contrast to previous findings in RASSF1A-ectopically
expressing cells, in that regulation of the cyclin D1 pro-
moter does not appear to be inhibited upon RASSF1A
expression [11]. However, expression of BLU in CNE-2
cells significantly inhibited the activity of the cyclin D1
promoter, as manifested by the different levels of the luci-
ferase gene co-expressed with pCD316-BLU (Figure 3B).
Transcription of cyclin D1 has been suggested to be regu-
lated by the c-Jun transcription factor, because of the pres-
ence of a c-Jun activation site on its promoter [11].
Modulation of JNK activity by BLU was tested by co-
transfection of the AP1 reporter, in which luciferase ex-
pression is driven by activated JNK. We found that BLU
dramatically blocks the reporter (Figure 3A) and leads to
the inhibition of c-Jun phosphorylation at a dose of 100
PFU per cell (Figure 3C and D).Conclusions
In recent years, human adenovirus (Ad) has been widely
used as a vector for gene transfer to mammalian cells,
owing to its ability to effectively infect a wide variety of
cells [20]. Replication deficient viruses proliferate for
weeks in hosts with cancer or other diseases, enabling
the restored expression of a defected gene to achieve
therapeutic goals. In the present study, a putative tumor
suppressor BLU was efficiently transferred to an NPC-
derived line CNE-2. CNE-2, together with cell lines of
identical histological origin, i.e. undifferentiated tumors
arising in the nasopharynx from the endemic region, ex-
hibit downregulated BLU expression as a result of pro-
moter methylation [8]. A dose-dependent infection
efficiency was observed.
The genesis of cancer is a multi-step event, and aber-
rations involving genes on the 3p21 region, including
homozygous deletions and promoter hypermethylation
affecting cluster of TSGs, are early molecular changes in
various human tumors [2]. Re-expression of the lost
TSGs complementary to other interventions, for ex-
ample, enhancement of host immune surveillance,
Figure 3 BLU expression downregulates cyclin D1 promoter and JNK activity, and inhibits phosphorylation of c-Jun. (A) CNE-2 cells
were transfected with pCD316 vector or pCD316-BLU, and cell lysates were immunoblotted and probed with goat anti-human BLU polyclonal
antibody. The membranes were stripped and re-probed with anti-actin mAb clone C4. (B) Expression of BLU inhibits cyclin D1 promoter
activity. pCD316 and pCD316p-BLU plasmids were co-transfected with cyclin D1 promoter reporter at concentration ratios of 1:1.5 and 1:4,
respectively. The luciferase activity was measured for the two conditions, and the reporter activity was presented as the ratio of the two. The
data are presented as the mean± SD, and are derived from at least three independent tests. *Indicates t< 0.05 when compared with the
measured values from the two groups. (C) pCD316-BLU and empty vector were co-transfected with JNK reporter at concentration ratios of
1:1.5 and 1:4, and the reporter activity was calculated. The data re presented as mean± SD, and were derived from at least three independent
tests. *Indicates P< 0.05 when comparing the calculated values for the relative light units between the two groups. (D) CNE-2 cells were
infected with 0, 10, 50 and 100 PFU Ad BLU (lanes 1, 2, 3, 4), and ectopic expression was demonstrated by immunoblotting and probing with
anti BLU goat polyclonal, anti actin mAb, anti phospho-c-Jun (P-c-Jun) and anti-c-Jun rabbit polyclonal antibodies. c-Jun phosphorylation was
inhibited by infection with 100 PFU Ad BLU.
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anti-cancer modalities. Our result prompts further
efforts to demonstrate the potential of transferred BLU
gene to inhibit in vivo tumor formation. The system
could be improved by replacing the ubiquitous promoter
derived from murine cytomegalovirus with a regulatory
element that has high activity in the malignancies to
control the expression of biotherapeutic target genes.
Such elements include α-fetoprotein enhancer-promoter
for hepatocellular carcinoma cells [21], and origin of
plasmid replication (OriP) element [22,23].
The current data, in part, mechanistically explain
BLU-mediated tumor suppression. It was demonstrated
in the present study that BLU inhibited clonogenic
growth of NPC and esophageal cancer cells in which en-
dogenous expression of BLU is absent. The inhibition of
colony formation may be due to the ability of BLU to in-
duce apoptosis or prevent cell cycle progression. TSGs
from the 3p region that were adenovirally transferred tolung cancer cells were tested for their potential to induce
apoptosis. While some genes indeed showed potential to
induce apoptosis, BLU had no effect on the initiation of
apoptosis [14]. Similar with this previously published
data [14], the NPC cells did not undergo apoptosis even
when exposed to high doses of Ad BLU, as evidenced by
no visible characteristic changes.
Therefore, growth inhibition by BLU may result
from the blocking of cell cycle entry. The entry to S
phase from G1 is controlled by cyclin D1 and other
cell cycle regulators. We have shown that cyclin D1
levels are significantly reduced in BLU-expressing
cells. Activation of the cyclin D1 promoter in re-
sponse to extracellular signals is dependent on the
binding of its AP1-like sequence following different
stimuli. It has been reported that the cyclin D1 gene
promoter is induced by c-Jun [11], but it remains to
be tested whether BLU regulates the upstream kinase
of c-Jun, JNK. Reporter assays revealed that similar to
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lower phosphorylation catalytic activity. An upstream
kinase which regulates the activity of JNK-AP1 axis,
apoptosis signal regulated kinase 1 (ASK1) has been
shown to be transcriptionally regulated by RASSF1A [9].
It has been suggested that that tumor suppressors pro-
teins with zinc finger domains may regulate cell prolif-
eration via transcription regulation. The reduced levels of
cyclin D1 may be due to transcriptional downregulation,
as BLU also inhibits the activity of its promoter, in con-
trast to the inhibition of its accumulation by RASSF1A
[10]. JNKs have been shown to serve as mediators of
apoptosis in response to cellular stress to sustain cell
proliferation [17], and have been implicated in survival in
response to extracellular stimuli such as cytokines. They
are serine/threonine protein kinases that can be activated
by a variety of stimuli including environmental stress
(UV and ionizing radiation, heat shock, osmotic or redox
shock), inflammatory cytokines, and growth factors. Dif-
ferent species of zinc finger proteins function to regulate
gene transcription, similar with ZNF418 [24], a member
of the zinc finger transcription factor family. BLU may
negatively regulate gene transcription mediated by the
MAPK signaling pathways through transcriptionally regu-
lating a molecule(s) yet to be identified. It has been
reported that the BLU promoter is stress-responsive [8],
and this implies an interaction between BLU and stress-
induced JNK. In addition, the effects of BLU on the up-
stream signaling molecule of the JNK pathway remain to
be explored.
It is therefore speculated that BLU inhibits JNK activ-
ity by transcriptional repression mediated through its
ZMYND domain, which is closely associated with co-
repressors such as nuclear co-repressor (NcoR), or his-
tone deacetylase, to regulate gene transcription [16]. The
present study revealed that JNK and cyclin D1 are tar-
gets of tumor suppression exerted by BLU.
In conclusion, a putative tumor suppressor, BLU, plays
a vital role in growth inhibition in NPC malignancies via
JNK and cyclin D1 promoter inhibition.Additional files
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